All 17 experts recently dismissed from a government vaccine advisory panel published an essay Monday decrying “destabilizing decisions" made by U.S. Health Secretary Robert F. Kennedy Jr. that could lead to more preventable disease spread.

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group. The mRNA-based RSV shot,

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.

For this reason, the CDC recommends adults 50 or older schedule the following vaccines, which many people can get for free. Just talk to your doctor before getting any vaccine, as there are some exceptions to CDC recommendations.

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group. The RSV shot,

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine,

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from respiratory syncytial virus,

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk for disease. Moderna's RSV shot,

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they contract respiratory syncytial virus. Previously the vaccine, sold under the name mResvia, was only licensed for use in adults aged 60 and older.

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants. The U.S. Food and Drug Administration (FDA) has approved a monoclonal antibody called Enflonsia, the drugmaker Merck announced June 9.